Citigroup Begins Coverage on Dianthus Therapeutics (NASDAQ:DNTH)

Research analysts at Citigroup began coverage on shares of Dianthus Therapeutics (NASDAQ:DNTH) in a report issued on Friday, Briefing.com reports. The brokerage set a “buy” rating and a $156.00 price target on the stock. Citigroup’s price target would indicate a potential upside of 44.65% from the company’s previous close.

A number of other brokerages have also issued reports on DNTH. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Truist Financial increased their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Guggenheim reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Wolfe Research restated an “outperform” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $126.92.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $107.85 on Friday. The firm has a market cap of $5.90 billion, a P/E ratio of -25.99 and a beta of 1.24. Dianthus Therapeutics has a 1 year low of $23.70 and a 1 year high of $117.88. The firm’s 50 day moving average price is $104.98 and its 200 day moving average price is $88.94.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). The business had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $0.30 million. Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%. As a group, equities analysts predict that Dianthus Therapeutics will post -3.83 EPS for the current year.

Insider Buying and Selling

In other news, EVP Simrat Randhawa sold 23,124 shares of Dianthus Therapeutics stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $106.41, for a total value of $2,460,624.84. Following the transaction, the executive vice president directly owned 4,000 shares of the company’s stock, valued at $425,640. The trade was a 85.25% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, Director Anne McGeorge sold 7,750 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $109.01, for a total value of $844,827.50. Following the sale, the director owned 1,250 shares of the company’s stock, valued at $136,262.50. The trade was a 86.11% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 283,678 shares of company stock worth $29,672,400. Corporate insiders own 3.02% of the company’s stock.

Hedge Funds Weigh In On Dianthus Therapeutics

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Dianthus Therapeutics by 24.7% during the fourth quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock valued at $84,417,000 after buying an additional 406,254 shares in the last quarter. UBS Group AG grew its position in shares of Dianthus Therapeutics by 342.6% in the 4th quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after acquiring an additional 469,547 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Dianthus Therapeutics by 1,275.3% in the 4th quarter. BNP Paribas Financial Markets now owns 475,749 shares of the company’s stock valued at $19,606,000 after acquiring an additional 441,156 shares during the last quarter. SummitTX Capital L.P. increased its holdings in shares of Dianthus Therapeutics by 13.8% in the 1st quarter. SummitTX Capital L.P. now owns 100,044 shares of the company’s stock valued at $8,396,000 after acquiring an additional 12,118 shares during the last quarter. Finally, California State Teachers Retirement System raised its position in shares of Dianthus Therapeutics by 155.5% during the 1st quarter. California State Teachers Retirement System now owns 40,584 shares of the company’s stock valued at $3,406,000 after acquiring an additional 24,697 shares in the last quarter. Hedge funds and other institutional investors own 47.53% of the company’s stock.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.